AI-generated research brief — verify at source
WNV-Neutralizing Plasma Misses Primary Endpoint but Signals Functional and Cognitive Benefit
In a small randomized trial of hospitalized patients with West Nile virus disease, treatment with donor-derived neutralizing plasma produced no reduction in the composite outcome of death or functional deterioration at 30 days compared to placebo — identical rates of 50% in both groups (RR 0.96, 95% CI 0.51–1.79). However, the intervention was associated with meaningfully better functional and cognitive scores at 30 days, and a numerically lower mortality rate, leaving the overall signal ambiguous and in need of larger confirmatory work.
What Was Studied
Researchers investigated whether donor-derived plasma containing West Nile virus (WNV)-neutralizing antibodies could reduce severe outcomes — specifically death or meaningful functional decline — among hospitalized patients with confirmed WNV disease. The question is clinically urgent because no approved antiviral therapy exists for WNV, and neuroinvasive disease in older or immunocompromised patients carries substantial morbidity and mortality.
How It Was Studied
This was a randomized, double-blind, placebo-controlled trial conducted in Israel during the country’s significant 2024 WNV outbreak. Eligible patients were either aged 60 years or older, or between 18 and 59 years of age and immunocompromised, all with laboratory-confirmed symptomatic WNV disease requiring hospitalization. A total of 34 participants were enrolled and assigned in a 2:1 ratio to the intervention (n=22) or placebo (n=12). The primary composite outcome — all-cause mortality or a greater than 5-point decrease on the Barthel Index for activities of daily living — was assessed at 30 days, with key secondary outcomes evaluated at both 30 and 90 days. The median participant age was 74 years, half were women, and 91% had neuroinvasive disease at enrollment, reflecting a predominantly severe patient population.
What Was Observed
- No difference in the primary composite outcome: Exactly half of patients in both the intervention and placebo groups experienced death or functional deterioration at 30 days (11/22 vs. 6/12; RR 0.96, 95% CI 0.51–1.79). This wide confidence interval indicates the result is highly imprecise and cannot exclude either meaningful benefit or harm.
- Numerically lower mortality with treatment, but not statistically conclusive: Mortality was 9% in the intervention group versus 33% in the placebo group (2/22 vs. 4/12), representing an approximately two-thirds lower observed risk (RR 0.33, 95% CI 0.09–1.15). However, the confidence interval spans a wide range and crosses 1.0, so this difference cannot be distinguished from chance with the available sample size.
- Better functional capacity at 30 days in the treated group: Median Barthel Index scores were higher in the intervention arm (85 vs. 78), reflecting modestly greater independence in daily activities — roughly a 15% relative improvement (RR 1.15, 95% CI 1.05–1.27).
- Improved cognitive scores at 30 days: Modified Mini-Mental State scores were higher in the treatment group (25 vs. 22 out of 30), representing approximately 24% better relative cognitive performance (RR 1.24, 95% CI 1.04–1.47). One allergic reaction (4.5%) was recorded in the intervention group, and no other notable safety signals were reported.
Why This Matters
This trial represents one of the first randomized evaluations of a pathogen-specific neutralizing plasma strategy for WNV disease, conducted under real outbreak conditions. The secondary findings — improved functional and cognitive outcomes — suggest biological plausibility for benefit, and the mortality signal, though statistically inconclusive, is notable enough to justify larger trials. The study also demonstrates that conducting controlled trials during emerging infectious disease outbreaks is feasible, even under considerable logistical constraints.
How to Read This Result
Given the very small sample size of only 34 participants, the trial was almost certainly underpowered to detect a true effect on the primary composite endpoint, and the wide confidence intervals across all outcomes mean that no finding — including the apparent mortality reduction — should be treated as definitive.
Limitations
The trial enrolled only 34 participants, severely limiting statistical power and producing imprecise estimates with wide confidence intervals for all outcomes, including mortality. The study was likely underpowered by design to reliably detect meaningful differences in the primary composite endpoint. Additionally, the cohort consisted almost entirely of patients with severe neuroinvasive WNV disease, which may restrict how broadly the findings apply to patients with milder presentations or different clinical profiles.